Advanced Search
    GUO Han-guo, CHEN Fei-li, ZHANG Fen, LUO Dong-lan, WEI Xiao-juan, HUANG Ling, JIANG Xin-miao, LIU Si-chu, LIANG Zhan-li, LIU Yan-hui, LI Wen-yu. Clinical Analysis of 36 Cases with Primary Refractory Diffuse Large B Cell LymphomaJ. Journal of Evidence-Based Medicine, 2018, 18(4): 236-240. DOI: 10.12019/j.issn.1671-5144.2018.04.012
    Citation: GUO Han-guo, CHEN Fei-li, ZHANG Fen, LUO Dong-lan, WEI Xiao-juan, HUANG Ling, JIANG Xin-miao, LIU Si-chu, LIANG Zhan-li, LIU Yan-hui, LI Wen-yu. Clinical Analysis of 36 Cases with Primary Refractory Diffuse Large B Cell LymphomaJ. Journal of Evidence-Based Medicine, 2018, 18(4): 236-240. DOI: 10.12019/j.issn.1671-5144.2018.04.012
    shu

    Clinical Analysis of 36 Cases with Primary Refractory Diffuse Large B Cell Lymphoma

      Abstract
    • Objective To investigate the survival ratio and factors affecting prognosis by analyzing clinical data. Methods Clinical data of 36 cases with primary refractory diffuse large B cell lymphoma admitted to Guangdong General Hospital were retrospectively analyzed. Results 5 patients refused further salvage treatment. First-line chemotherapy are anthracycline-based regimens combined with or without rituximab. The salvage treatment regimens are DICE, GDP, DHAP, CEPP, Lenalidomide and GA101. Median second progression free survival time is 1.7 months with 2 year second progression free survival rate being 5.0%. Median second overall survival time is 7.9 months with 2 year second overall survival rate being 25.9%. Univariate analyses showed that high IPI, bulky disease and B symptom influenced the prognosis. Conclusions Patients with primary refractory diffuse large B cell lymphoma have poor prognosis and can't benefit from regular salvage chemotherapy.
      • FullText(HTML)
    • loading
      • References (16)
      • Related Articles

    Catalog

      Turn off MathJax
      Article Contents

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return